ALN-HTT02 Investigational RNAi therapy targeting huntingtin in Phase 1 development for Huntington’s disease, with Alnylam leading the partnered clinical program.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-HTT02.
Add it to your Products I use list and share why you use it.